CN104870008B - 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途 - Google Patents

噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途 Download PDF

Info

Publication number
CN104870008B
CN104870008B CN201380061794.6A CN201380061794A CN104870008B CN 104870008 B CN104870008 B CN 104870008B CN 201380061794 A CN201380061794 A CN 201380061794A CN 104870008 B CN104870008 B CN 104870008B
Authority
CN
China
Prior art keywords
seq
amino acid
disease
protein
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380061794.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104870008A (zh
Inventor
R.克里施南
R.费希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clara Biosciences Ltd By Share Ltd
Original Assignee
Clara Biosciences Ltd By Share Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clara Biosciences Ltd By Share Ltd filed Critical Clara Biosciences Ltd By Share Ltd
Publication of CN104870008A publication Critical patent/CN104870008A/zh
Application granted granted Critical
Publication of CN104870008B publication Critical patent/CN104870008B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380061794.6A 2012-10-02 2013-10-01 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途 Expired - Fee Related CN104870008B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261708709P 2012-10-02 2012-10-02
US61/708,709 2012-10-02
US201261730316P 2012-11-27 2012-11-27
US61/730,316 2012-11-27
US201361801349P 2013-03-15 2013-03-15
US61/801,349 2013-03-15
US201361828105P 2013-05-28 2013-05-28
US61/828,105 2013-05-28
PCT/US2013/062862 WO2014055515A1 (en) 2012-10-02 2013-10-01 Use of p3 of bacteriophage fusion proteins as amyloid binding agents

Publications (2)

Publication Number Publication Date
CN104870008A CN104870008A (zh) 2015-08-26
CN104870008B true CN104870008B (zh) 2019-10-01

Family

ID=49354958

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380061794.6A Expired - Fee Related CN104870008B (zh) 2012-10-02 2013-10-01 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途

Country Status (25)

Country Link
US (3) US9688728B2 (el)
EP (1) EP2906235B1 (el)
JP (1) JP6283366B2 (el)
KR (1) KR102101258B1 (el)
CN (1) CN104870008B (el)
AR (1) AR092879A1 (el)
AU (1) AU2013327472B2 (el)
BR (1) BR112015007424A2 (el)
CY (1) CY1120132T1 (el)
DK (1) DK2906235T3 (el)
EA (1) EA033666B1 (el)
ES (1) ES2641373T3 (el)
HK (1) HK1213775A1 (el)
HR (1) HRP20171413T1 (el)
HU (1) HUE036893T2 (el)
IL (1) IL238021B (el)
LT (1) LT2906235T (el)
MX (1) MX358755B (el)
NZ (1) NZ706838A (el)
PL (1) PL2906235T3 (el)
PT (1) PT2906235T (el)
SI (1) SI2906235T1 (el)
TW (1) TWI613212B (el)
WO (1) WO2014055515A1 (el)
ZA (1) ZA201502940B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857539C (en) 2011-11-29 2021-08-03 Neurophage Pharmaceuticals, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
EP3003349B1 (en) 2013-05-28 2018-12-12 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
MX2017007059A (es) * 2014-12-03 2018-05-02 Proclara Biosciences Inc Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación.
TW202336236A (zh) * 2015-03-27 2023-09-16 美商再生元醫藥公司 偵測生物污染物之組成物及方法
US10995152B2 (en) 2016-10-26 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
EP3806884B1 (en) 2018-06-15 2023-08-02 Amyl Therapeutics General amyloid interaction motif (gaim)
EP4177256A1 (en) 2020-07-06 2023-05-10 Molgenbio Co., Ltd. Tricyclic dilactone compound, and production method and use thereof
WO2023230282A1 (en) * 2022-05-25 2023-11-30 The General Hospital Corporation Modulation of bace1 as a therapy for spinocerebellar ataxia
WO2024119183A1 (en) 2022-12-02 2024-06-06 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031611A2 (en) * 2001-10-05 2003-04-17 Cangene Corporation Phagemid display system
WO2004018685A2 (de) * 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive fusionsproteine und verfahren zu ihrer herstellung
CN101166536A (zh) * 2005-02-01 2008-04-23 雷蒙特亚特特拉维夫大学有限公司 治疗与淀粉样蛋白沉积有关的炎症和涉及已活化小胶质细胞的脑部炎症的方法
WO2009143465A1 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method of imaging abnormal deposits or plaques
CN102405231A (zh) * 2009-03-20 2012-04-04 Lfb生物技术公司 优化的Fc变体

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
SG47099A1 (en) 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DK0615451T3 (da) 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6376117B1 (en) 2000-07-18 2002-04-23 Sofco L.P. Internal fuel staging for improved fuel cell performance
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
AU2002233340B2 (en) 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
BR0207945A (pt) 2001-03-08 2004-07-27 Merck Patent Ges Mit Beschroen Fator estimulante de colÈnia de macrófagos granulócitos modificados (gm-csf) com reduzida imunogenicidade
AU2007214399A1 (en) 2006-02-15 2007-08-23 Ramot At Tel-Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2007094003A2 (en) 2006-02-15 2007-08-23 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2007114139A1 (ja) 2006-04-06 2007-10-11 Fumiaki Uchiyama 新規繊維状ファージによるファージディスプレイ
US20090324554A1 (en) 2006-07-21 2009-12-31 Ramot At Tel Aviv University Ltd. Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates
AU2007306102B2 (en) 2006-10-11 2012-02-23 Antitope Limited T cell epitope databases
US20110286970A1 (en) 2008-11-24 2011-11-24 Ramot At Tel Aviv University Ltd. Method for treating parkinson's disease
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
JP2014509514A (ja) * 2011-03-11 2014-04-21 ラモット アット テルアヴィブ ユニヴァーシティ リミテッド 神経変性タウオパシーを治療するための方法
CA2857539C (en) 2011-11-29 2021-08-03 Neurophage Pharmaceuticals, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
EP3003349B1 (en) 2013-05-28 2018-12-12 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
MX2017007059A (es) 2014-12-03 2018-05-02 Proclara Biosciences Inc Polipéptidos que comprenden una secuencia de aminoácidos modificada de bacteriófago g3p, que carece de señal de glicosilación.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031611A2 (en) * 2001-10-05 2003-04-17 Cangene Corporation Phagemid display system
WO2004018685A2 (de) * 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive fusionsproteine und verfahren zu ihrer herstellung
CN101166536A (zh) * 2005-02-01 2008-04-23 雷蒙特亚特特拉维夫大学有限公司 治疗与淀粉样蛋白沉积有关的炎症和涉及已活化小胶质细胞的脑部炎症的方法
WO2009143465A1 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method of imaging abnormal deposits or plaques
CN102405231A (zh) * 2009-03-20 2012-04-04 Lfb生物技术公司 优化的Fc变体

Also Published As

Publication number Publication date
US10208090B2 (en) 2019-02-19
TW201418279A (zh) 2014-05-16
KR20150063544A (ko) 2015-06-09
LT2906235T (lt) 2017-10-25
US20180354994A1 (en) 2018-12-13
MX358755B (es) 2018-09-03
HUE036893T2 (hu) 2018-08-28
BR112015007424A2 (pt) 2021-04-20
WO2014055515A1 (en) 2014-04-10
KR102101258B1 (ko) 2020-04-16
PT2906235T (pt) 2017-09-28
NZ706838A (en) 2017-06-30
HRP20171413T1 (hr) 2017-12-15
AU2013327472B2 (en) 2017-10-26
PL2906235T3 (pl) 2017-12-29
US9688728B2 (en) 2017-06-27
AU2013327472A2 (en) 2015-06-04
EA033666B1 (ru) 2019-11-14
AU2013327472A1 (en) 2015-05-21
TWI613212B (zh) 2018-02-01
ES2641373T3 (es) 2017-11-08
EA201590690A1 (ru) 2016-04-29
HK1213775A1 (zh) 2016-07-15
ZA201502940B (en) 2017-11-29
CY1120132T1 (el) 2018-12-12
JP2015532290A (ja) 2015-11-09
IL238021A0 (en) 2015-05-31
JP6283366B2 (ja) 2018-02-21
US20170305975A1 (en) 2017-10-26
US10526377B2 (en) 2020-01-07
MX2015004119A (es) 2015-10-26
SI2906235T1 (sl) 2017-12-29
US20150376239A1 (en) 2015-12-31
DK2906235T3 (en) 2017-09-25
IL238021B (en) 2019-06-30
EP2906235B1 (en) 2017-07-19
CN104870008A (zh) 2015-08-26
AR092879A1 (es) 2015-05-06
EP2906235A1 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
CN104870008B (zh) 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途
US11732023B2 (en) Engineered polypeptides
JP6494565B2 (ja) オリゴマー特異アミロイドベータエピトープおよび抗体
CN110506055A (zh) 工程改造的转铁蛋白受体结合多肽
JP2022513798A (ja) トランスフェリン受容体標的ペプチド
US10151762B2 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
TR201815563T4 (tr) Anti-alfa sinüklein bağlayıcı moleküller.
TR201812636T4 (tr) İnsan anti-tau antikorları.
CN107531781B (zh) 用于阿尔茨海默病和相关紊乱的抗体分子和肽递送系统
CN107325168B (zh) 一种经修饰的生长分化因子及其制备方法和应用
CN109996812A (zh) 用于诊断和治疗重症肌无力的肽及其用途
CN107250154A (zh) 包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽
CN110506054A (zh) 经工程改造的多肽

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: NEUROPHAGE PHARMACEUTICALS, Inc.

Address before: Massachusetts, USA

Applicant before: NEUROPHAGE PHARMACEUTICALS, INC.

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191001

CF01 Termination of patent right due to non-payment of annual fee